Fosun Pharma stock trades at EUR 0.10 as buyback advances

Published on 09/29/2026 at 13:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fosun Pharma stock is tied to a 62,000-share repurchase for HKD 1.08 million on September 25, 2026. H1 revenue rose 4.75 percent to CNY 20.442 billion.

Fosun Pharma, CNE100000536, Illustration mit AI erstellt.

Fosun Pharma stock was at EUR 0.10 at Lang & Schwarz on September 29, 2026, at 1:43 p.m. CEST, while the company continued its H-share repurchase program. Futunn reported that Fosun Pharma repurchased 62,000 shares for HKD 1.08 million on September 25, 2026.

Buyback reaches HKD 1.00 billion

On September 6, 2026, Fosun Pharma announced an H-share repurchase plan of up to HKD 1.00 billion. The shares may be cancelled or held as treasury shares, and the company said the program would be funded primarily by proceeds from selling a 6.00 percent stake in Gland Pharma for USD 294.00 million.

The repurchase is paired with capital allocation for research and development and debt repayment. The company retained an approximately 45.76 percent stake in Gland Pharma after the transaction, keeping the unit consolidated in its accounts.

H1 growth favors innovative drugs

For the six months ended June 30, 2026, Fosun Pharma reported revenue of CNY 20.442 billion, up 4.75 percent year over year, according to Fosun Pharma. Profit attributable to shareholders excluding non-recurring gains and losses increased 19.09 percent to CNY 1.144 billion, while operating cash flow rose 13.59 percent to CNY 2.424 billion.

Seeking Alpha reported that innovative-drug revenue reached CNY 4.911 billion in H1 2026, up 13.84 percent, while research and development spending rose 25.66 percent to CNY 3.247 billion. The mix shows a faster expansion in innovative medicines than in total revenue.

Shanghai listing stays in view

The primary A-share listing is 600196 on the SSE, while 6ix identifies 2196 on the HKEX as an alternate listing. On the SSE, the stock was last at CNY 23.39 on September 29, 2026, at 3:00 p.m. CST, against a 52-week range of CNY 20.85 to CNY 30.09 and a market capitalization of CNY 61.7 billion.

Price stays at EUR 0.10

Fosun Pharma stock was trading at EUR 0.10 at Lang & Schwarz on September 29, 2026, at 1:43 p.m. CEST. The reference quote has no valid daily percentage comparison because the prior-close field was unavailable.